NewLink Genetics Corp (NLNK) Receives $27.00 Consensus Target Price from Brokerages

NewLink Genetics Corp (NASDAQ:NLNK) has been given a consensus recommendation of “Buy” by the seven analysts that are presently covering the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $31.20.

NLNK has been the subject of a number of research reports. Zacks Investment Research cut shares of NewLink Genetics Corp from a “hold” rating to a “sell” rating in a report on Tuesday, April 4th. SunTrust Banks, Inc. raised shares of NewLink Genetics Corp from a “hold” rating to a “buy” rating and upped their target price for the company from $12.00 to $30.00 in a report on Thursday, March 30th. Jefferies Group LLC upped their target price on shares of NewLink Genetics Corp from $12.00 to $15.00 and gave the company a “hold” rating in a report on Wednesday, March 1st. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $26.00 target price on shares of NewLink Genetics Corp in a report on Thursday, April 6th.

Several hedge funds have recently made changes to their positions in NLNK. FMR LLC boosted its stake in shares of NewLink Genetics Corp by 119.3% in the fourth quarter. FMR LLC now owns 904,856 shares of the biotechnology company’s stock worth $9,302,000 after buying an additional 492,330 shares during the period. Columbus Circle Investors boosted its stake in shares of NewLink Genetics Corp by 155.6% in the first quarter. Columbus Circle Investors now owns 343,041 shares of the biotechnology company’s stock worth $8,267,000 after buying an additional 208,816 shares during the period. Knoll Capital Management LP purchased a new stake in shares of NewLink Genetics Corp during the third quarter worth about $1,504,000. Northwest Wealth Management LLC purchased a new stake in shares of NewLink Genetics Corp during the fourth quarter worth about $863,000. Finally, Orbimed Advisors LLC boosted its stake in shares of NewLink Genetics Corp by 2.8% in the fourth quarter. Orbimed Advisors LLC now owns 1,991,700 shares of the biotechnology company’s stock worth $20,475,000 after buying an additional 53,400 shares during the period. 46.83% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://sportsperspectives.com/2017/04/21/analysts-set-newlink-genetics-corp-nlnk-price-target-at-27-00-updated-updated.html.

NewLink Genetics Corp (NASDAQ:NLNK) traded down 0.55% during midday trading on Monday, reaching $18.16. The company’s stock had a trading volume of 929,587 shares. NewLink Genetics Corp has a 12 month low of $9.23 and a 12 month high of $25.17. The company’s market cap is $530.56 million. The stock has a 50-day moving average price of $19.83 and a 200 day moving average price of $14.50.

NewLink Genetics Corp (NASDAQ:NLNK) last announced its earnings results on Tuesday, February 28th. The biotechnology company reported ($0.46) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.66) by $0.20. NewLink Genetics Corp had a negative net margin of 303.49% and a negative return on equity of 56.48%. The business earned $12.70 million during the quarter, compared to analysts’ expectations of $4.31 million. Analysts expect that NewLink Genetics Corp will post ($2.80) earnings per share for the current fiscal year.

About NewLink Genetics Corp

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

5 Day Chart for NASDAQ:NLNK

Receive News & Ratings for NewLink Genetics Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply